The association between the use of antipsychotics and diabetes mellitus (DM) is still unclear, as depicted by several conflicting reports. Our study aims to assess the risk of DM in new users of antipsychotics.
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Clinical Implications
• The risk of DM increases with duration of exposure to any antipsychotic treatment.
• The risk of DM could be reversed when antipsychotics are stopped.
• The risk of DM does not seem to be different across atypical antipsychotics.
Limitations
• Some factors known to increase the risk of DM are not captured by the RAMQ administrative database and, therefore, could not be accounted for: family history of DM, physical activity level, and food habits.
• A pharmacy claim for a drug does not confirm that the drug has actually been used.
A ntipsychotics are principally used in the treatment of schizophrenia and BDs. 1 They are also used to treat behavioural disturbances associated with dementia and many other mental health-related conditions. 1 There is some evidence that atypical antipsychotics may increase the risk of DM. Clinical trial data suggest that clozapine and olanzapine users are more at risk than patients treated with either quetiapine, risperidone, or ziprasidone to have a plasma glucose elevation or a diminution of insulin sensitivity. [2] [3] [4] Conversely, observational epidemiologic studies have shown an increased risk of DM for users of atypical antipsychotics, compared with nonusers. 5, 6 Such an increased risk has also been observed for users of olanzapine, compared with users of typical antipsychotics 7 or with users of risperidone. [8] [9] [10] [11] Likewise, it has been shown that users of clozapine or quetiapine, 10 compared with risperidone, have an increased risk of DM. And finally, users of clozapine or olanzapine seem also to be more at risk than patients treated with typical antipsychotics to develop elevations in plasma glucose 12 or DM. 9, [13] [14] [15] By contrast, conflicting results were also reported. In a 12-week clinical trial, no significant changes in glucose metabolism parameters were observed for any of the groups studied (haloperidol, olanzapine, and risperidone). 16 Moreover, it has been observed that the risk of DM was not statistically different between olanzapine and risperidone, or when comparing olanzapine and clozapine to the typical antipsychotic haloperidol. 17 Miller et al 18 observed a lower risk of DM among people on risperidone than among those on a typical antipsychotic. The observed risk of DM for users of quetiapine, olanzapine, and clozapine was not statistically different than the risk for typical antipsychotics. Finally, compared with proton pump inhibitor users, the risk of developing DM was not increased among both typical and atypical antipsychotic users. 19 Discrepancies observed between reported results may be due to limitations in study design. For example, the use of antipsychotics may vary with time, the proportion of people discontinuing their treatment or switching to another drug being high, 20 yet in many studies, 4, [11] [12] [13] [14] 18, 19 it has been assumed that the antipsychotic used at entry in the cohort was taken continuously, that is, without taking into consideration therapy discontinuation or switching. In other studies, the follow-up period was lower than 4 months 2, 16, 21 or not clearly defined, 17 or potentially confounding variables-such as type of mental disorder, obesity, use of drugs (other than antipsychotics) considered to predispose to weight gain or to DM, comorbidities, and individual characteristics-were not considered. [2] [3] [4] [21] [22] [23] [24] As a consequence, the risk of DM associated with individual antipsychotics remains unclear. Therefore, we conducted a population-based study that was designed to compare the risk of DM in patients who used different antipsychotics in Quebec. The study addressed key study design limitations of previously published similar studies.
Methods
Study Design and Data Sources
Using data from the Quebec Health Insurance Board (RAMQ) and from the Quebec hospitalization registry, we performed a nested case-control study. The RAMQ health insurance plan covers all 7.5 million permanent residents of the province of Quebec for both medical services and hospitalizations. The RAMQ public drug plan covers all residents aged 65 years or over, welfare recipients, and those who are ineligible for a private drug insurance group plan.
We obtained data from the RAMQ beneficiary (age, sex, region of residence, type of beneficiary to the drug plan, date of death-if applicable, and date of the beginning and end of eligibility to the health insurance plan) and the physicians' statistiquement différent pour tous les antipsychotiques atypiques. Une exposition plus longue à tout antipsychotique (pour chaque période de 30 jours, RC 1,009; IC à 95 % 1,006 à 1,011) et l'utilisation courante d'antipsychotiques (RC 1,26; IC à 95 % 1,17 à 1,36) étaient associées au DS.
Conclusion :
Ces résultats suggèrent que les paramètres métaboliques des personnes exposées aux antipsychotiques devraient être surveillés, sans égard au médicament administré, parmi les médicaments disponibles au moment de l'analyse.
billing (date of medical visits and the primary diagnosis for those visits) databases. We also obtained the following data on dispensed drugs from the RAMQ drug plan database: prescription fill date, drug name, dose and dosage form, treatment duration (that is, the number of days' supply), and the prescriber's specialty. The RAMQ drug plan database is considered to be accurate for prescription claims. 25 From the hospitalization registry, we obtained data on hospitalization dates, length of stay, primary diagnosis, and secondary diagnoses. As each beneficiary is identified in both the RAMQ and hospitalization databases by a unique and anonymous identification number, it is possible to link information pertaining to one person from all of these databases.
The Commission d'accès à l'information du Québec and the Centre hospitalier affilié universitaire de Québec's research ethics committee approved the conduct of the study.
Study Population
The RAMQ first identified all drug plan beneficiaries who were dispensed at least 1 prescription of any antipsychotic between January 1, 2000, and December 31, 2007. During this period, the Quebec public drug plan reimbursed prescriptions of typical antipsychotics and of the following atypical antipsychotics: clozapine, olanzapine, quetiapine, and risperidone. People who were ineligible to the public drug plan during the entire 365-day period before the first antipsychotic dispensing on or after January 1, 2000, were excluded. For each remaining person, RAMQ sent data encompassing the period beginning 365 days before the date of their first dispensing of any antipsychotics on or after January 1, 2000, and ending on December 31, 2007. We then excluded people who had their first antipsychotic claim after December 31, 2007, because hospitalization data were unavailable after this date. We excluded people aged less than 20 years at the date of their first dispensing. We did so because younger people are less likely to develop type 2 DM, compared to middle-aged people. Likewise, we excluded people of more than 64 years of age at the date of their first dispensing as they are more likely to develop type 2 DM than middle-aged people and as antipsychotics are primarily prescribed in this population to treat symptoms of dementia, compared with the treatment of schizophrenia or BDs. Finally, we excluded people who had 1 or more claims of an antipsychotic in the 365-day period prior to the first antipsychotic dispensing on or after January 1.
The final dataset for the analysis was a large cohort of new users of antipsychotics, between the ages of 20 and 64 years. Within this cohort, we created a DM-free subcohort that included all people who had no recorded diagnosis of DM (ICD-9 code 250) or claims for an antidiabetic (Anatomical, Therapeutic and Chemical [commonly referred to as ATC] classification, 26 class A10) during the 365 days preceding the date of the first dispensing of any antipsychotic. All people included in the DM-free subcohort were followed from the date of their first antipsychotic claim until death, end of eligibility to the drug plan, or December 31, 2007, whichever came first.
Case-Control Definition
Cases (that is, subjects) were all people who had at least one claim for an antidiabetic or a diagnosis of DM in the physicians claim or hospitalization databases, during their follow-up period. The date of the first occurrence of either condition was set as the index date. Controls (that is, control subjects) were selected using the density sampling method. 27 The index date for each subject was used to define the risk sets, from which potential control subjects were chosen. Potential control subjects for a particular subject were all people who met the following 4 criteria: entered the cohort during the same year as the subject; were of the same age at cohort entry as the subject; were of the same sex as the subject; and were still in the cohort at the subject's index date. We randomly selected 10 control subjects for each subject and assigned them their subject's index date. Thus the observation period (that is, the period between the date of the first antipsychotic claim [included] and the index date [excluded]) is similar for subjects and control subjects in each risk set in terms of years.
Variables
Exposure to Antipsychotics
To describe exposure to antipsychotics, we defined 3 variables taking into account different drug use patterns: the antipsychotic drug; the number of 30-day periods of use; and antipsychotic use at index date. The antipsychotic variable had 6 values (typical antipsychotic only, clozapine only, olanzapine only, quetiapine only, risperidone only, or polytherapy). To give a value to a person, we searched the drug plan database for all antipsychotic claims recorded during the observation period. Except for users of typical antipsychotics, users of more than one drug (at least one atypical antipsychotic and at least one other antipsychotic [typical or atypical]) were put in the polytherapy category. Users of more than one typical antipsychotic were classified in the typical antipsychotic only category. The number of 30-day periods of use equals the number of 30-day periods during which a person had any antipsychotic available during the observation period. This variable was assessed using the date of prescription fill and the number of days' supply recorded for all antipsychotic claims. The days' supply numbers were first summed, then, using the fill dates, we retrieved the number of days covered by more than one claim. As no information is available on the in-hospital use of drugs, we assumed that people on antipsychotic treatment at the time of hospitalization continued to be exposed during their hospital stay. In the analyses, the number of 30-day periods of use was defined as a 30-day continuous variable. Antipsychotic use at index date was defined based on the last drug claim recorded in the database before the index date. A person was deemed as a current user if their index date was included in the period between the date of the last drug claim and the date of the end of its days' supply, to which a permissible gap period, equal to one-half the number of days' supply, was added. Otherwise, people were considered past users.
Potentially Confounding Variables
We took into account potentially confounding variables pertaining to each person (mental disorder, obesity, residency area, and beneficiary type) and their use of any drug considered to potentially cause weight gain or predispose to DM. We also considered comorbidity indicators, such as number of different drugs acquired and use of health services (number of medical visits and hospitalizations). Type of mental disorder (ICD-9: 290-319) and obesity (ICD-9: 278.00, 278.01, and 278.02) were defined using hospitalization and physicians' billing data recorded during the 365-day period before the date of the first antipsychotic claim. Residency area, prescriber's specialty, and beneficiary type were measured at cohort entry, while the following variables were measured during the observation period: hospitalization for any cause (yes or no), number of outpatient physician visits for any cause, number of different drugs acquired (other than antipsychotics), and proportion of time during which a person used drugs other than an antipsychotic that can potentially cause weight gain or predispose to DM. The proportion of time during which a person used the above-mentioned drugs was defined as the number of days for which at least one of those drugs was available, divided by the number of days in the observation period. This last variable could take 1 of the 4 following values: 0%, between more than 0% and 20%, between more than 20% and 80%, and more than 80%.
Statistical Analysis
We used frequency distributions to describe matching characteristics of the study population. Paired multivariate logistic regression analyses were used to assess the association between exposure variables and DM. Odds ratios computed this way have been shown to be equivalent to hazard ratios estimated with Cox proportional hazard models. 27 Typical antipsychotic users were used as the reference group. We also computed 95% confidence intervals. Multicollinearity was assessed using the procedure described by Belsley et al. 28 Analyses were performed using SAS, version 9.1. 29 
Results
Among the 88 467 people included in our DM-free subcohort, 6109 subjects with DM were identified during the follow-up period (incidence rate of DM: 2.43 per 100 person-year [95% CI 2.37 to 2.49]) and 61 090 matched control subjects were selected. Characteristics of subjects and control subjects, for matching variables, are shown in Table 1 .
The risk of developing DM was lower among new users of quetiapine than among those of typical antipsychotics ( 
Discussion
An important finding emerged from our study. We observed that a longer duration of exposure to any antipsychotic treatment was associated with an increased risk of DM. Indeed, the risk of DM was increased by 0.9% for each 30day period of exposure (10.8% during 1 year). This finding is consistent with results reported by Gianfrancesco et al, 8 who found that each 1-month increment of treatment with olanzapine, high-potency conventional antipsychotics, low-potency conventional antipsychotics, or clozapine increased the odds of type 2 DM in treated patients, compared with untreated patients. However, this relation was not observed by these researchers for risperidone. Our finding is also consistent with results of Dunlop et al, 12 who have observed that, for each additional year of exposure to olanzapine or to a typical antipsychotic, people were 1.6 times more likely to have an elevated random glucose level during their follow-up. The risk of DM was higher among current users of any antipsychotic than among past users. This finding is also in line with the results of a recently published article 30 reporting that, in a population of new users of antipsychotics aged 66 years or more, current users of antipsychotics were more at risk than past users to be hospitalized for hyperglycaemia. Our finding suggests that although the risk of DM increases with the duration of exposure to any antipsychotic, this increased risk could be reversed when exposition is stopped.
Compared with users of typical antipsychotics, there was no increase in the risk of DM among new users of olanzapine, risperidone, or clozapine. This finding is concordant with results reported in other studies, [13] [14] [15] 18 although care should be taken when interpretating our results pertaining to clozapine as the number of people exposed to this drug a Adjusted for obesity and type of mental disorder in the 365-day period before antipsychotic treatment initiation, for residency area, beneficiary type, and specialty of prescribing physician at antipsychotic treatment initiation, and for the following variables measured during the observation period: number of different drugs used (antipsychotics excluded), number of medical visits for any cause, hospitalization for any cause (yes or no), and proportion of time during which the person had possession of any of the drugs considered to predispose to weight gain or to DM or hyperglycemia. in our population was low. Conversely, people exposed to quetiapine had a decreased risk. However, as shown by overlapping 95% confidence intervals around odds ratios, the risk of DM was not different across atypical antipsychotics. This finding is also consistent with clinical trial results that have recently been reported by Perez-Iglesias et al. 16 These authors found no difference between risperidone and olanzapine concerning their impact on glucose and insulin levels.
Conversely, our results contrast with those of past studies, in which the development of DM was observed to be associated with the use of olanzapine 9, 11, 13, 14 or clozapine. 15 However, duration of exposure was not measured in any of these latter studies. Therefore, the increased risk of DM for olanzapine or clozapine users that was observed in the past could be a result of confounding, given these drugs may have been taken for a longer duration than other antipsychotics, in particular, olanzapine, which has been associated with better persistency. 3, 31 In our study, we have overcome one major limitation of previous studies in which exposure to antipsychotics may not have been measured with accuracy. For example, in at least 5 clinical trials, 2, 3, 16, 21, 24 patients were assumed to take the initial antipsychotic throughout the study period, with no attempt to measure adherence to treatment. In many observational studies, 4, [11] [12] [13] [14] 18, 19, 23, 32 people were considered to be exposed throughout the study period to the atypical antipsychotic initially prescribed, therefore assuming people would neither discontinue their drug treatment nor be switched to another drug. In some studies, exposure was simply defined as the fill of a prescription for an antipsychotic within 3 months, 9 6 months, 5 or 7 to 12 months 5 before apparition of the outcome variable. In one study, 13 people were censored from the cohort when they were switched to another antipsychotic.
As exposure to antipsychotics is likely to vary with time, the nested case-control approach of our study design enabled to accurately measure drug exposure in the period preceding the index date, thus taking into account drug switches and discontinuation that happened in the observation period. For example, matching subjects and control subjects by time has allowed the stratification of exposure based on current or past use. Not surprisingly, our results are concordant with those reported by researchers 33 who considered exposure in different time periods, like we did. They found that 1 month of treatment with olanzapine increased the likelihood of type 2 DM treatment by 3% above that of patients with untreated psychosis.
Our study is subject to some limitations inherent in the use of administrative databases. First, we assumed that drugs dispensed were used by patients. Second, the incidence of DM has probably been underestimated as people who have DM but have neither been diagnosed nor prescribed an antidiabetic were not taken into account. Third, we did not have access to data on factors known to increase the risk of DM, such as family history, physical activity level, or food habits. Therefore, the absence of an elevated risk ratio for olanzapine could be due to an indication bias. Such a bias cannot be ruled out as during the observation period it had become widely suspected that olanzapine could cause DM. 1 Therefore, it is possible that patients who initially had a higher risk of DM were less likely to be prescribed olanzapine, this drug being reserved for patients perceived at lower risk for DM. We have tried to minimize this bias by adjusting for obesity, a covariate that we observed to be associated with a 3-fold increase in the risk of DM. Moreover, as there were only few users of clozapine, the association between the use of this drug and the risk of DM might not have been assessed accurately. This is further illustrated by the large 95% confidence interval around the odds ratio. Last, duration of exposure was assessed in terms of 30-day periods of exposure to any antipsychotics. Therefore, whether the risk of DM increases with the duration of exposure to a particular antipsychotic, rather than any other one, remains unknown.
Control subjects were matched to subjects on the year of cohort entry. Therefore, the observation period between subjects and control subjects was not identical for a number of 30-day periods of observation between the date of the first antipsychotic claim and the index date. Indeed, the mean number of 30-day periods of exposure was higher among subjects than control subjects for all categories of drugs but clozapine (data not shown). This finding is consistent with our observation of an association between the duration of exposure to any antipsychotic and the increased risk of DM.
Finally, atypical antipsychotics, such as aripiprazole and ziprasidone, that seem to exert favourable effects regarding glucose parameters 23, 24 were not included, and thus the findings of our study cannot be generalized to these 2 atypical antipsychotics.
Conclusion
In conclusion, in this nested case-control study, compared with new users of typical antipsychotics, the risk of DM in new users of clozapine, olanzapine, and risperidone was similar, whereas new users of quetiapine had a reduced risk. The risk of DM was not different across the atypical antipsychotics. Conversely, the risk of DM was increased as the duration of exposure to any antipsychotic increases. This risk was also higher among current users of antipsychotics. These findings suggest that metabolic parameters of patients requiring long-term use of antipsychotics included in our study should be monitored closely, irrespective of the antipsychotic taken.
